Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) – Stock analysts at William Blair cut their Q4 2025 earnings estimates for shares of Axsome Therapeutics in a research note issued to investors on Tuesday, November 26th. William Blair analyst M. Minter now anticipates that the company will post earnings of $0.10 per share for the quarter, down from their previous estimate of $0.18. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($4.75) per share.
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.38) by $0.04. The company had revenue of $104.76 million for the quarter, compared to analysts’ expectations of $98.71 million. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. During the same period in the previous year, the company posted ($1.32) EPS.
Get Our Latest Analysis on AXSM
Axsome Therapeutics Stock Performance
NASDAQ:AXSM opened at $99.65 on Thursday. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97. Axsome Therapeutics has a fifty-two week low of $64.11 and a fifty-two week high of $105.00. The stock has a market cap of $4.83 billion, a PE ratio of -15.26 and a beta of 1.26. The firm’s fifty day simple moving average is $91.48 and its 200-day simple moving average is $85.67.
Insider Transactions at Axsome Therapeutics
In other news, Director Mark E. Saad sold 11,016 shares of the stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $91.31, for a total transaction of $1,005,870.96. Following the transaction, the director now directly owns 10,002 shares in the company, valued at $913,282.62. This represents a 52.41 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 22.40% of the company’s stock.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of AXSM. Arizona State Retirement System increased its position in Axsome Therapeutics by 2.1% during the 2nd quarter. Arizona State Retirement System now owns 8,630 shares of the company’s stock worth $695,000 after purchasing an additional 177 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Axsome Therapeutics by 22.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock worth $156,000 after purchasing an additional 318 shares in the last quarter. Northwestern Mutual Wealth Management Co. acquired a new stake in Axsome Therapeutics during the 2nd quarter worth approximately $27,000. WCM Investment Management LLC increased its position in Axsome Therapeutics by 0.3% during the 3rd quarter. WCM Investment Management LLC now owns 113,692 shares of the company’s stock worth $10,191,000 after purchasing an additional 347 shares in the last quarter. Finally, US Bancorp DE increased its position in Axsome Therapeutics by 0.3% during the 3rd quarter. US Bancorp DE now owns 133,126 shares of the company’s stock worth $11,964,000 after purchasing an additional 421 shares in the last quarter. 81.49% of the stock is currently owned by hedge funds and other institutional investors.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
See Also
- Five stocks we like better than Axsome Therapeutics
- Financial Services Stocks Investing
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- What is Insider Trading? What You Can Learn from Insider Trading
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- What Are Dividend Challengers?
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.